Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The value of teclistamab in R/R myeloma & strategies to mitigate toxicities

Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, comments on the recent approval of teclistamab for the treatment of relapsed/refractory (R/R) multiple myeloma, emphasizing the value of this agent in the R/R space. Dr Richter also discusses the importance of preventing toxicities with this agent and further summarizes various strategies being followed to mitigate these toxicities. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultant/advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Abbvie, Genentech
Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies